---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-23-000378"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T11:50:23.222385+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemed Q3 revenue +7.2% to $565M; raises FY2023 adjusted EPS guidance to $19.82-$20.02

## Summary
- GAAP diluted EPS $4.93 (+30.4% YoY); adjusted diluted EPS $5.32 (+24.9%).
- VITAS net patient revenue $334M (+12.5%), ADC 18,859 (+9.4%), adjusted EBITDA margin 16.5% (+441 bps).
- Roto-Rooter revenue $231M (+0.4%), adjusted EBITDA $66.9M (-3.7%), margin 29.0% (-124 bps).
- Full-year adjusted EPS guidance raised to $19.82-$20.02 from $18.72-$18.92, includes $1.18/sh retention costs.
- Ended quarter with $173M cash, no debt; repurchased $14.3M in shares at avg $504.07.

## SEC filing metadata
- accession: 0001562762-23-000378
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/che-20230930x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-23-000378
- JSON: https://secwatch.observer/filing/0001562762-23-000378.json
- Plain text: https://secwatch.observer/filing/0001562762-23-000378.txt

## Key facts
- Earnings Releases
  CHEMED CORP reported third quarter ended September 30, 2023 results: revenue $565 million, EPS $4.93. Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $565 million
  - EPS: $4.93
  - Guidance: raised
  - Result: reported results
  source text: and after-tax expense for the Retention Program was $9.6 million and $7.1 million, respectively.  Results for Quarter Ended September 30, 2023  · Revenue increased 7.2% to $565 million · GAAP Diluted Earnings-per-Share (EPS) of $4.93, an increase of 30.4% · Adjusted Diluted EPS of $5.32, an increase of 24.9%   VITAS segment operating results: · Net Patient
  evidence_url: https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm
- Earnings Releases
  CHEMED CORP updated its quarter ended September 30, 2023 guidance (raised).
  - Period: quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On October 25, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/19584/000156276223000378/0001562762-23-000378-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.